Compare HESTER PHARM with NATURAL CAPS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

HESTER BIOSCIENCES vs NATURAL CAPS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    HESTER BIOSCIENCES NATURAL CAPS HESTER BIOSCIENCES/
NATURAL CAPS
 
P/E (TTM) x 47.1 31.3 150.3% View Chart
P/BV x 8.1 7.0 114.7% View Chart
Dividend Yield % 0.5 0.2 215.7%  

Financials

 HESTER BIOSCIENCES   NATURAL CAPS
EQUITY SHARE DATA
    HESTER BIOSCIENCES
Mar-21
NATURAL CAPS
Mar-21
HESTER BIOSCIENCES/
NATURAL CAPS
5-Yr Chart
Click to enlarge
High Rs2,278140 1,627.0%   
Low Rs93434 2,710.9%   
Sales per share (Unadj.) Rs251.9127.6 197.3%  
Earnings per share (Unadj.) Rs40.811.1 367.5%  
Cash flow per share (Unadj.) Rs56.418.0 313.3%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Avg Dividend yield %0.61.1 54.3%  
Book value per share (Unadj.) Rs268.399.7 269.2%  
Shares outstanding (eoy) m8.516.23 136.6%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x6.40.7 932.2%   
Avg P/E ratio x39.47.9 500.6%  
P/CF ratio (eoy) x28.54.8 587.1%  
Price / Book Value ratio x6.00.9 683.4%  
Dividend payout %24.59.0 271.9%   
Avg Mkt Cap Rs m13,661544 2,512.8%   
No. of employees `000NANA-   
Total wages/salary Rs m38970 558.5%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m2,143795 269.6%  
Other income Rs m477 641.6%   
Total revenues Rs m2,190802 272.9%   
Gross profit Rs m653133 492.1%  
Depreciation Rs m13343 309.2%   
Interest Rs m665 1,214.0%   
Profit before tax Rs m50192 547.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m15422 686.8%   
Profit after tax Rs m34769 502.0%  
Gross profit margin %30.516.7 182.6%  
Effective tax rate %30.724.5 125.5%   
Net profit margin %16.28.7 186.2%  
BALANCE SHEET DATA
Current assets Rs m1,615419 385.1%   
Current liabilities Rs m614339 181.2%   
Net working cap to sales %46.710.2 460.1%  
Current ratio x2.61.2 212.5%  
Inventory Days Days1346 28.9%  
Debtors Days Days84122,546,289 0.0%  
Net fixed assets Rs m2,495551 452.9%   
Share capital Rs m8562 136.5%   
"Free" reserves Rs m2,198559 393.5%   
Net worth Rs m2,283621 367.7%   
Long term debt Rs m8280-   
Total assets Rs m4,110970 423.6%  
Interest coverage x8.617.8 48.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.8 63.6%   
Return on assets %10.07.7 130.8%  
Return on equity %15.211.1 136.5%  
Return on capital %18.215.6 116.7%  
Exports to sales %16.617.0 97.6%   
Imports to sales %00-   
Exports (fob) Rs m357135 263.2%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m357135 263.2%   
Fx outflow Rs m2162 33.9%   
Net fx Rs m33674 455.7%   
CASH FLOW
From Operations Rs m581126 460.9%  
From Investments Rs m-384-156 246.2%  
From Financial Activity Rs m-18228 -661.3%  
Net Cashflow Rs m-23-2 975.0%  

Share Holding

Indian Promoters % 44.3 56.6 78.3%  
Foreign collaborators % 9.5 0.0 -  
Indian inst/Mut Fund % 1.0 1.2 77.9%  
FIIs % 0.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 46.3 43.4 106.5%  
Shareholders   15,017 6,118 245.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare HESTER BIOSCIENCES With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)

After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

Wait! Don't Buy the Smallcap 'Dip' Just Yet(Profit Hunter)

Jun 20, 2022

Why this may not be the best time to buy smallcaps.

5 Consistent Compounding Stocks Available at Discount. Time to Buy?(Views On News)

Jun 22, 2022

The good side of a market correction? Investors get consistent compounding stocks at a discount.

Looking for Value Stocks Amid Volatile Times? Consider These 5 Stocks(Views On News)

Jun 20, 2022

These value stocks have the potential to deliver good returns in the long run. Watch out for them.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

HESTER BIOSCIENCES SHARE PRICE


Jul 1, 2022 (Close)

TRACK HESTER BIOSCIENCES

  • Track your investment in HESTER BIOSCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON HESTER BIOSCIENCES

HESTER BIOSCIENCES 5-YR ANALYSIS

COMPARE HESTER BIOSCIENCES WITH

MARKET STATS